Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR101-80 Injection vs GZR33 and Insulin Aspart in Healthy Participants
NCT07918898Phase 1Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Feb 2027
01
Overview
Phase 1 trial of GZR101 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Area under the curve for Insulin Aspart from 0 to 6 hours and Area under the curve for GZR33 from 0 to 24 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
GZR101
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07918898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918898.